Document Detail

Iatrogenic myelomonocytic leukemia following melphalan treatment of scleromyxedema.
MedLine Citation:
PMID:  3470169     Owner:  NLM     Status:  MEDLINE    
We report the case of a patient with scleromyxedema with abnormal monoclonal gamma globulin of the kappa type who was treated with melphalan (Alkeran), an alkylating agent. After nine and one-half years of therapy, the patient showed myelomonocytic leukemia. The risk of secondary malignancies must be considered when weighting the benefits and risks of melphalan treatment.
F Helm; T N Helm
Related Documents :
15763979 - Second malignancies and richter's syndrome in patients with chronic lymphocytic leukemia.
8833399 - Thrombosis in patients with acute promyelocytic leukemia treated with and without all-t...
1545569 - A pilot study of carboplatin augmentation therapy for patients with poor risk acute non...
272799 - Rapid cytoreduction in acute leukemia. management of cerebral leukostasis by cell phere...
6192899 - Red cell aplasia in myelofibrosis with myeloid metaplasia. a distinct functional and cl...
17652839 - Immunophenotypic subtyping of leukemic cells from iranian patients with acute lymphobla...
22545149 - Chlamydia pneumoniae-specific ige is prevalent in asthma and is associated with disease...
2011159 - Dysphagia in patients with the post-polio syndrome.
2322009 - State of leukocyte adhesiveness/aggregation in the peripheral blood of pemphigus and ps...
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  Cutis     Volume:  39     ISSN:  0011-4162     ISO Abbreviation:  Cutis     Publication Date:  1987 Mar 
Date Detail:
Created Date:  1987-05-12     Completed Date:  1987-05-12     Revised Date:  2013-09-12    
Medline Journal Info:
Nlm Unique ID:  0006440     Medline TA:  Cutis     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  219-23     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Diabetes Mellitus, Type 1 / complications
Leukemia, Myeloid / chemically induced*
Melphalan / adverse effects*
Paraproteinemias / blood,  complications*
Scleroderma, Systemic / complications,  drug therapy,  physiopathology*
Reg. No./Substance:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Elimination of enoxacin in renal disease.
Next Document:  Selective repression of RNA polymerase II by microinjected phosvitin.